Pharmacokinetics of Regorafenib by endogenous cortisol 6beta-hydroxylation clearance and potential of personalized use.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Mar 2018
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer; Gastrointestinal cancer
- Focus Adverse reactions
- 12 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 11 Mar 2015 New trial record